CPT code 79005 – Oral radiopharmaceutical therapy

Key takeaways

CPT code 79005 reports radiopharmaceutical therapy by oral administration, and the route decides the code, not the dose.

Report 79005 once for each oral therapeutic dose, because no separate code exists for a repeat treatment.

Dose calculation and the risk and benefit discussion are included, while a documented E/M service is reported separately.

The radiopharmaceutical goes on its own HCPCS Level II line, such as A9517 for I-131 capsules, billed per millicurie.

Codes 79000 and 79001 were deleted on January 1, 2005, so a claim that still carries them is rejected as invalid.

CPT code 79005 is billed by route, not by dose

CPT code 79005 is the Category I code for radiopharmaceutical therapy, by oral administration. The American Medical Association places it in the Radiopharmaceutical Therapy subsection (79005-79999) of Nuclear Medicine, within the Radiology chapter. The code is route-based, so it applies to any therapeutic radiopharmaceutical the patient takes by mouth.

There is no dose tier and no millicurie threshold. Most 79005 claims involve sodium iodide I-131, given as a capsule or an oral solution for hyperthyroidism or thyroid cancer.

What is included: The code covers the oral administration of the therapeutic dose and the dose calculation. It also covers the risk and benefit discussion with the patient.

What is reported separately: Any separately documented E/M service, plus the radiopharmaceutical supply on its own HCPCS line. Diagnostic thyroid uptake or imaging studies, such as 78014, also go on their own lines.

The indication changes the paperwork, not the code

Because the code follows the route, the indication never changes the CPT code. It does change the ICD-10 code and the paperwork the payer wants.

• Hyperthyroidism: Graves disease and toxic nodular goiter are treated with oral I-131, often after antithyroid drugs have failed or caused side effects. Codes from the E05 category support the claim.
• Differentiated thyroid cancer: After a total or near-total thyroidectomy for papillary or follicular carcinoma, oral I-131 ablates remnant tissue or treats residual disease. C73 anchors this claim.
• Other oral therapeutic agents: Any other radiopharmaceutical given by mouth for therapy also reports as 79005. The descriptor names the route, not a drug.

The indication also shapes prior authorization. Cancer cases usually need pathology and operative reports. Hyperthyroidism cases usually need thyroid function tests and, where one was done, an uptake study.

Each route has its own radiopharmaceutical therapy code

Since January 1, 2005, radiopharmaceutical therapy codes have been organized by route of administration. Pick the code that matches how the agent entered the body, then report it once per administration. An intravenous dose, for example, is billed as 79101, never as 79005.

No dedicated code exists for a repeat or subsequent oral treatment. When a patient returns for a second I-131 dose, 79005 is reported again for that administration. A lower hyperthyroid dose and a higher cancer dose also report the same way.

Dose still matters on the claim, just in a different place. The administered activity in millicuries sets the units on the HCPCS supply line, covered next.

The I-131 supply is billed per millicurie on its own line

CPT 79005 pays for giving the dose. The radiopharmaceutical itself goes on its own HCPCS Level II line, and the therapeutic I-131 codes are billed per millicurie.

Units equal the administered activity, so a 100 mCi capsule dose is billed as A9517 with 100 units. Check the units against the administration record before submission, not against the order alone.

ICD-10 codes for 79005: Keep C73 primary during treatment

Payers check medical necessity by matching the ICD-10 code on the claim to the procedure. For 79005, the diagnosis must reflect a condition treated with oral radiopharmaceutical therapy.

ICD-10-CM guidelines reserve Z85 history codes for cancers that were excised with no further treatment directed at the site. Radioiodine given to ablate remnant tissue or treat residual disease is treatment, so C73 stays primary. Reporting Z85.850 in its place invites a medical-necessity denial.

Modifiers for 79005 depend on who bills each component

Modifier choice depends on who bills which part of the service, and on whether another code billed that day triggers an edit.

Confirm the professional and technical split for 79005 in the current fee schedule file before you set up -26 and -TC billing. A global claim sent after the facility has billed -TC triggers a duplicate claim edit. Never add -59 by default, because without an edit to bypass it only adds audit risk.

Medicare pays CPT code 79005 differently by setting

Medicare pays 79005 under different systems depending on where the service happens. The rates sit in the Centers for Medicare and Medicaid Services Physician Fee Schedule tools.

• Physician Fee Schedule (MPFS): Payment for the professional component or global service is built from work, practice expense and malpractice RVUs. The total is multiplied by the conversion factor and adjusted by locality. Check the MPFS Look-Up Tool for the current-year rate before you quote it.
• Hospital outpatient (OPPS): Hospitals report 79005 under its assigned APC, with the radiopharmaceutical on its own HCPCS line. Confirm the current APC and status indicators in Addendum B each year.

Commercial rates are set by contract. Tracking allowed amounts by payer shows where 79005 is underpaid, which is the job of revenue cycle management.

Radioactive iodine therapy often needs prior authorization

Many commercial payers and Medicare Advantage plans require prior authorization for oral radiopharmaceutical therapy. Rules differ by plan, so check each policy before you schedule the treatment date.

Start the authorization package as soon as the order is signed. Most requests for 79005 draw on the following documents:

1. Physician order naming the agent, the oral route, the prescribed activity in mCi and the clinical rationale.
2. Diagnostic evidence: a pathology report for thyroid cancer, or thyroid function tests and any uptake results for hyperthyroidism.
3. Surgical history for cancer cases, such as the operative report confirming total or near-total thyroidectomy.
4. Pre-treatment labs for cancer cases, typically TSH, thyroglobulin and anti-thyroglobulin antibodies.
5. Radiation safety and release plan under NRC regulations (10 CFR Part 35).

Radiology benefit managers such as eviCore review nuclear medicine requests for some plans. Check the payer’s provider portal to see who handles the review before you submit.

How a 79005 claim moves from order to payment

A clean 79005 claim is built in the same order as the treatment. Each step adds one piece the payer later checks against the others.

1. Order and authorization: The physician orders the agent, the oral route and the activity in mCi. The authorization request goes out with that order.
2. Treatment day: The dose is calculated, the risks are discussed and the patient takes the capsule or solution. The administration record logs the activity given.
3. Coding: 79005 goes on the claim with the diagnosis that drove treatment. The supply code follows, with units equal to the administered mCi.
4. Review and submission: A biller checks each claim line against the chart. Only then does the claim go to the payer or clearinghouse.
5. Payment or denial: The remittance advice comes back. A denial usually points at one line, and that line is where the fix starts.

Put together, those steps produce a claim with three or four lines. Each line answers to a different part of the chart, as the diagram below shows.

Check the chart against the claim before you submit

The medical record must support every line on the claim. Under medical billing compliance standards, a 79005 chart should show the following before submission.

• Physician order: The agent, the oral route, the prescribed activity in mCi and the indication.
• Administration record: The date and time, the form given (capsule or solution), the administered activity and the lot number.
• Dose calculation and risk discussion: Both belong to 79005, so record them in the procedure note rather than an E/M note.
• Separate E/M note, if billed: It must show work beyond the dose calculation and risk discussion, such as the workup and decision to treat.
• Radiation safety instructions: Written and verbal precautions given to the patient, including contact restrictions after release.
• Pre-treatment workup: Relevant labs and, for cancer cases, the low-iodine diet and thyroid hormone withdrawal or recombinant TSH preparation.

Meeting clean claim requirements means the chart, the CPT line and the supply line agree before the claim goes out. The administered mCi in the record should match the units on the HCPCS line exactly.

Common 79005 denials, and the fix for each

A 79005 claim carries two paid lines, the procedure and the supply, so a mismatch on either one stalls payment. Each denial below can be caught with a check before submission.

Use our guide to denial codes in medical billing to trace each claim adjustment reason code on the remittance advice back to its billing error.

How claims management software keeps 79005 claims moving

Many 79005 problems start when the order, the administration record and the claim live in separate systems. Billing staff then reconcile them by hand, often only after a denial arrives.

Pabau, the practice software we build, keeps patient records, appointments and billing in one place. Its claims tools for practices send US claims through Claim.MD, the clearinghouse Pabau integrates with.

Payer responses come back into the same system, so your team can follow each 79005 claim from submission to payment. Coding decisions such as the route code, supply units and modifiers stay with your coders.

Follow every 79005 claim to payment

Pabau sends US claims through Claim.MD and brings payer responses back into one system. Your team sees where each nuclear medicine claim stands without switching tools.

Book a demo

Conclusion

CPT code 79005 is simpler than older references suggest. The route decides the code, so an oral therapeutic dose reports as 79005 whether it is the first treatment or the third.

The risk now sits in the lines around it. Match the supply units to the administered activity, keep C73 primary while therapy targets the cancer, and bill E/M only when the note supports it.

Clear the 2005 deletions out of your templates first, because that fix takes minutes and stops a whole run of rejections. Book a demo to see how Pabau follows each radioiodine claim from submission to payment.

Continue your research

Billing an IV radiopharmaceutical instead? CPT code 79101 covers intravenous radiopharmaceutical therapy and its HCPCS drug lines.

Billing the uptake scan before treatment? CPT code 78014 explains thyroid imaging with uptake and how it sits beside therapy claims.

Coding the thyroid cancer diagnosis? ICD-10 code C73 covers malignant neoplasm of the thyroid gland and when it stays primary.

Need to read denial reason codes on a remittance? Denial codes in medical billing maps CARC codes to their root causes and standard appeal responses.

Want a clearinghouse that supports 837P electronic claims? How Claim.MD clearinghouse works with Pabau explains the submission, eligibility and ERA workflow end to end.

Frequently asked questions